Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Placebo Controlled 2-Arm Parallel Group, Multicenter Study With A 16-Week Treatment Assessing The Efficacy And Safety, And 52-Week Long Term Safety Including 36-Week Open Label Extension Of Tofogliflozin With Insulin Treatment In Type 2 Diabetes Mellitus

NCT02201004 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02201004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02201004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Placebo Controlled 2-Arm Parallel Group, Multicenter Study With A 16-Week Treatment Assessing The Efficacy And Safety, And 52-Week Long Term Safety Including 36-Week Open Label Extension Of Tofogliflozin With Insulin Treatment In Type 2 Diabetes Mellitus
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2014
Completion date
October 31, 2016
Enrollment
211 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus